stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Altman Z-score
Exelixis, Inc.'s Altman Z-score for fiscal 2025 is 12.68, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 12.68 | 2.65 |
| FY2024 | 10.04 | 2.18 |
| FY2023 | 7.86 | 1.32 |
| FY2022 | 6.54 | (3.46) |
| FY2021 | 10.00 | (5.42) |
| FY2020 | 15.41 | (1.90) |
| FY2019 | 17.32 | (10.18) |
| FY2018 | 27.49 | 14.74 |
| FY2017 | 12.76 | 12.42 |
| FY2016 | 0.33 | 7.53 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.36 | — | 0.44 | |
| Retained earnings / total assets | (0.03) | — | −0.04 | |
| EBIT / total assets | 0.31 | — | 1.01 | |
| Market value of equity / total liabilities | 17.42 | — | 10.45 | |
| Sales / total assets | 0.82 | — | 0.82 | |
| Altman Z-score | Safe zone | 12.68 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 7.69 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EXEL Exelixis, Inc. | 12.7× |
| INSM Insmed, Inc. compare | 9.3× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.3× |
| HALO Halozyme Therapeutics, Inc. compare | 3.5× |
| ASND Ascendis Pharma A/S compare | 2.0× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.4× |
| SMMT Summit Therapeutics PLC compare | 0.9× |
| BBIO BridgeBio Pharma, Inc. compare | −3.5× |
| BNTX BioNTech SE Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement